Meeting News CoverageVideo

VIDEO: New approaches demonstrate potential to exploit immune system to treat cancer

NEW ORLEANS — Kunle Odunsi, MD, PhD, FRCOG, FACOG, deputy director of Roswell Park Cancer Institute and executive director of the institute’s Center for Immunotherapy, spoke to HemOnc Today at the American Association for Cancer Research Annual Meeting about advances in the use of immunotherapy for cancer treatment.

“This has been an outstanding meeting because it focuses on a lot of new discoveries and new approaches for how to use the body’s immune system to treat cancer,” Odunsi said.

Odunsi spotlighted advances in the use of neoantigens and checkpoint inhibitors, as well as adoptive cellular therapy.

“There are now new avenues for exploiting the immune system to help patients with cancer,” Odunsi said. “We expect that, in a matter of time, almost every patient will have some form of immunotherapy incorporated into their treatment plan.”

NEW ORLEANS — Kunle Odunsi, MD, PhD, FRCOG, FACOG, deputy director of Roswell Park Cancer Institute and executive director of the institute’s Center for Immunotherapy, spoke to HemOnc Today at the American Association for Cancer Research Annual Meeting about advances in the use of immunotherapy for cancer treatment.

“This has been an outstanding meeting because it focuses on a lot of new discoveries and new approaches for how to use the body’s immune system to treat cancer,” Odunsi said.

Odunsi spotlighted advances in the use of neoantigens and checkpoint inhibitors, as well as adoptive cellular therapy.

“There are now new avenues for exploiting the immune system to help patients with cancer,” Odunsi said. “We expect that, in a matter of time, almost every patient will have some form of immunotherapy incorporated into their treatment plan.”

    See more from American Association for Cancer Research Annual Meeting